AZTA vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AZTA exhibits mixed financial health with a weak Piotroski F-Score of 4/9, indicating borderline stability, and lacks an Altman Z-Score to assess distress risk. While the company shows strong revenue visibility and improving earnings trends, elevated valuation metrics (P/E of 77.02 vs. sector average of 220.68) and negative profit margins (-9.39%) raise concerns. Recent insider selling and declining long-term price performance contrast with a positive short-term rebound and solid quarterly earnings surprises. The stock trades significantly above the Graham Number of $20.99, suggesting potential overvaluation relative to defensive criteria.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
AZTA vs LLY: Head-to-Head Comparison
This page compares Azenta, Inc. (AZTA) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.